Saridon
| Combination of | |
|---|---|
| Propyphenazone | Analgesic |
| Paracetamol | Analgesic |
| Caffeine | Stimulant |
| Clinical data | |
| Trade names | Saridon |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
By mouth |
| ATC code | |
| Identifiers | |
| ChemSpider |
|
Propyphenazone/paracetamol/caffeine (trade name Saridon) is an analgesic combination indicated for the management of headache. It contains the analgesics propyphenazone and paracetamol and the stimulant caffeine.
Saridon was first launched by Roche in 1933, initially containing pyrithyldione and phenacetin, widely used remedies for fever and pain. It often contained aspirin, phenacetin and caffeine, but was reformulated in 1981, replacing the original ingredient phenacetin with paracetamol, before phenacetin was banned by the US FDA in 1983. It was available in more than 80 countries across Europe, Latin America, Asia and Africa, but has been discontinued in many of them.
This combination is used for the relief of pain such as headache, toothache, menstrual discomfort, pain and fever associated with colds and flu, and for postoperative and rheumatic pain.
Paracetamol, an analgesic and antipyretic substance, has slow onset but has a longer duration of action and is lacking anti-inflammatory properties. On the other hand, propyphenazone, a non-steroidal anti-inflammatory drug (NSAID), is proven to have a faster onset but shorter duration of action. The combination of paracetamol and propyphenazone increases and prolongs the therapeutic activity of propyphenazone: peak blood plasma concentrations increase by about 40%, and the elimination half-life is prolonged to about 77 minutes. Caffeine, with a stimulating effect, is a drug that wards off drowsiness and restores alertness. It also enhances the analgesic potency of paracetamol, although a Cochrane review concluded that a dose of 100 mg is needed for an effect – double the amount contained in Saridon.
...
Wikipedia